Inflammation: planning for a source of pharmacokinetic/pharmacodynamic variability in translational studies.
The impact of inflammation on variability in the pharmacokinetics (PK) and pharmacodynamics (PD) of drugs should be considered in the design, analysis, and interpretation of clinical pharmacology studies. Data suggest that the metabolism and transport of drugs, as well as the expression of receptors, may change in the presence of inflammation. The clinical implications of these changes are not straightforward; they may vary depending on whether the inflammation is active or controlled and may change with time and successful treatment of the inflammation.
Department of Clinical Pharmacology/Modeling and Simulation, GlaxoSmithKline, Research Triangle Park, North Carolina, USA. ginny.d.schmith@gsk.com
V D
VD
Schmith
J F
JF
Foss
D000818:Animals; D001692:Biological Transport; D002986:Clinical Trials as Topic / Q000379:methods*; D005786:Gene Expression Regulation; D006801:Humans; D007249:Inflammation / Q000503:physiopathology*; D004364:Pharmaceutical Preparations / Q000378:metabolism*
D004364:Pharmaceutical Preparations